Veoza, or fezolinetant, a non-hormonal daily pill, works on the brain's temperature-control centre.
A drug that aims to prevent hot flushes has been approved for use in the UK - potentially benefitting hundreds of thousands of women.
Women can be prescribed Veoza from January after facing decades with few treatment options.
The drug Veoza, also known as fezolinetant, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) after receiving similar approval ...
Veoza targets the brain's temperature control centre, and will be available from January onwards through private prescriptions only. | ITV National News.
Veoza, also known as fezolinetant, has been given the green light by the UK regulator, potentially benefitting millions of women.
A drug that can potentially offer relief to hundreds of thousands of women battling hot flushes during menopause has been approved in the UK.
The drug could prove to be an alternative to hormone replacement therapy, HRT, which aims to relieve menopause symptoms by replacing the hormones oestrogen ...
Astellas' drug fezolinetant (Veoza) has been approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the prevention of hot flashes ...
Veoza reduces the severity of this common menopausal symptom. But at ยฃ430 a month, only the wealthy will benefit just now, says Guardian columnist Devi ...
Fezolinetant, marketed as Veoza, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) for moderate to severe vasomotor symptoms ...